Reuss Reviews the Development of LP-300 in Advanced NSCLC

Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Lantern Pharma, we had the pleasure of speaking with Joshua Eric Reuss, MD, a thoracic medical oncologist at MedStar Health in Washington DC, about the development of LP-300 in advanced non–small cell lung cancer.

Originally designed as a neuroprotective agent for chemotherapy, LP-300 was evaluated in a phase 3 trial (NCT00966914) in combination with carboplatin and paclitaxel in patients with advanced lung adenocarcinoma. Although the agent did not meet the prespecified end point in the trial, retrospective findings indicated that the addition of chemotherapy to LP-300 led to a significant improvement in overall and 2-year survival of 91% and 125%, respectively, compared with chemotherapy alone in the never-smoker subgroup.

In July 2022, the FDA green light the multicenter, open-label phase 2 HARMONIC trial (NCT05456256), in which Lantern Pharma will evaluate LP-300 in combination with carboplatin and pemetrexed (Alimta) vs carboplatin and pemetrexed alone in the never-smoker patient population. The primary end point of the study is progression-free survival and overall survival.

In our exclusive interview, Dr Reuss discussed the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, potential reasons why the agent may have enriched activity in never-smokers, and its ongoing investigation in the phase 2 HARMONIC trial.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Lantern Pharma. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.